Literature DB >> 23050103

Circulating tumor-derived biomarkers in lung cancer.

Aline Taenzer1, Catherine Alix-Panabières, Harriet Wikman, Klaus Pantel.   

Abstract

Entities:  

Year:  2012        PMID： 23050103      PMCID： PMC3461065          DOI： 10.3978/j.issn.2072-1439.2012.08.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis.

Authors:  Ruifeng Zhang; Fangchun Shao; Xiaohong Wu; Kejing Ying
Journal:  Lung Cancer       Date:  2009-12-11       Impact factor: 5.705

2.  Circulating tumor cell as a diagnostic marker in primary lung cancer.

Authors:  Fumihiro Tanaka; Kazue Yoneda; Nobuyuki Kondo; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Shakibur Rahman; Noriaki Tsubota; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

Review 3.  Circulating tumor cells and circulating tumor DNA.

Authors:  Catherine Alix-Panabières; Heidi Schwarzenbach; Klaus Pantel
Journal:  Annu Rev Med       Date:  2011-11-02       Impact factor: 13.739

Review 4.  MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment.

Authors:  Qiming Wang; Sheng Wang; Huijuan Wang; Peng Li; Zhiyong Ma
Journal:  Exp Biol Med (Maywood)       Date:  2012-02-16

Review 5.  Personalized medicine in lung cancer: what we need to know.

Authors:  Tony S K Mok
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

6.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

Authors:  Matthew G Krebs; Robert Sloane; Lynsey Priest; Lee Lancashire; Jian-Mei Hou; Alastair Greystoke; Tim H Ward; Roberta Ferraldeschi; Andrew Hughes; Glen Clack; Malcolm Ranson; Caroline Dive; Fiona H Blackhall
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

7.  Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.

Authors:  Carina Roth; Sabine Kasimir-Bauer; Klaus Pantel; Heidi Schwarzenbach
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

Review 8.  Detection, clinical relevance and specific biological properties of disseminating tumour cells.

Authors:  Klaus Pantel; Ruud H Brakenhoff; Burkhard Brandt
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

Review 9.  Review: Biological relevance of disseminated tumor cells in cancer patients.

Authors:  Sabine Riethdorf; Harriet Wikman; Klaus Pantel
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

10.  Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.

Authors:  A Lecharpentier; P Vielh; P Perez-Moreno; D Planchard; J C Soria; F Farace
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640
View more
  7 in total

1.  Expression and significance of miRNA-21 and BTG2 in lung cancer.

Authors:  Qing Sun; Meng Hang; Xuedan Guo; Wenlong Shao; Guangqiao Zeng
Journal:  Tumour Biol       Date:  2013-07-16

Review 2.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Authors:  Marius Ilie; Véronique Hofman; Elodie Long; Olivier Bordone; Eric Selva; Kevin Washetine; Charles Hugo Marquette; Paul Hofman
Journal:  Ann Transl Med       Date:  2014-11

3.  Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.

Authors:  Galina S Zamay; Olga S Kolovskaya; Tatiana N Zamay; Yury E Glazyrin; Alexey V Krat; Olga Zubkova; Ekaterina Spivak; Mohammed Wehbe; Ana Gargaun; Darija Muharemagic; Mariia Komarova; Valentina Grigorieva; Andrey Savchenko; Andrey A Modestov; Maxim V Berezovski; Anna S Zamay
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

4.  High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients.

Authors:  Ana Koren; Matija Rijavec; Eva Sodja; Izidor Kern; Aleksander Sadikov; Viljem Kovac; Peter Korosec; Tanja Cufer
Journal:  Oncotarget       Date:  2017-04-11

5.  Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.

Authors:  Sander Brinkhof; Harry J M Groen; Sabine S Siesling; Maarten J IJzerman
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

Review 6.  Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment.

Authors:  Jialing Zhang; Stephan Stanislaw Späth; Sadie L Marjani; Wengeng Zhang; Xinghua Pan
Journal:  Precis Clin Med       Date:  2018-06-14

Review 7.  Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.

Authors:  Loredana G Marcu
Journal:  J Pers Med       Date:  2020-11-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.